Serina Therapeutics (SER) Total Non-Current Liabilities (2022 - 2025)

Serina Therapeutics has disclosed Total Non-Current Liabilities across 4 years of filings, most recently posting $3.7 million for Q2 2025.

• In Q2 2025, Total Non-Current Liabilities fell 72.63% year-over-year to $3.7 million; the TTM figure through Jun 2025 stood at $3.7 million (down 72.63% YoY), while the FY2024 annual figure was $2.6 million, down 45.78% from the prior year.
• Total Non-Current Liabilities came in at $3.7 million for Q2 2025 at Serina Therapeutics, up from $2.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $32.2 million in Q1 2023 to a low of -$8.9 million in Q1 2024.
• Average Total Non-Current Liabilities over 4 years is $10.8 million, with a median of $13.2 million recorded in 2022.
• Year-over-year, Total Non-Current Liabilities soared 153.62% in 2023 and slumped 127.69% in 2024.
• Over 4 years, Total Non-Current Liabilities stood at $20.4 million in 2022, then tumbled by 76.16% to $4.9 million in 2023, then plunged by 45.78% to $2.6 million in 2024, then jumped by 42.22% to $3.7 million in 2025.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $3.7 million in Q2 2025, $2.6 million in Q1 2025, and $2.6 million in Q4 2024.